Cargando…
Decreased expression of acetyl‐CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma
Metastasis is a serious risk that may occur during the treatment of hepatocellular carcinoma (HCC), preventing many patients from being surgical candidates and contributing to poor prognosis. Hypoxia has been proved an important factor of metastasis through the epithelial–mesenchymal transition (EMT...
Autores principales: | Sun, Lin, Kong, Yinlong, Cao, Manqing, Zhou, Hongyuan, Li, Huikai, Cui, Yunlong, Fang, Feng, Zhang, Wei, Li, Jiafeng, Zhu, Xiaolin, Li, Qiang, Song, Tianqiang, Zhang, Ti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497799/ https://www.ncbi.nlm.nih.gov/pubmed/28387999 http://dx.doi.org/10.1111/cas.13252 |
Ejemplares similares
-
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016) -
Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017) -
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016) -
Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report
por: Hou, Zhenyu, et al.
Publicado: (2020) -
Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
por: Hou, Zhenyu, et al.
Publicado: (2020)